STING1 and STING-associated vasculopathy with onset in infancy: Nevertheless, HHMX prevented the development of SAVI in the SAVI mouse model bearing the heterozygous STING N153S mutation, suggesting that HHMX may function as a potent immunotherapeutic agent to prevent the exacerbation of disease progression (Figures 5E–H).